Once-daily indacaterol 75 μg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients’ perceived onset of effect

BACKGROUND: Indacaterol 75 μg once daily is a long-acting β(2) agonist approved for maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD). The purpose of this study was to evaluate patients’ perception of onset of effect with a single dose. METHODS: In th...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Siler, Thomas M, LaForce, Craig F, Kianifard, Farid, Williams, James, Spangenthal, Selwyn
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2014
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4159068/
https://ncbi.nlm.nih.gov/pubmed/25214778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S67356
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares